title: Successful Treatment of Ulcerative Colitis With Vedolizumab in a Patient With an Infliximab-Associated Psoriasiform Rash.
abstract: Psoriatic skin lesions associated with anti-tumor necrosis factor (TNF) agents are well-described in the medical literature. However, the etiology and optimal management of this condition remain unclear. Vedolizumab is a novel, gut-specific, anti-integrin agent used for the treatment of inflammatory bowel disease (IBD). We report a case of infliximab-associated psoriasiform lesions in an ulcerative colitis patient. Transition to vedolizumab resulted in resolution of the cutaneous lesions without recurrence and remission of his ulcerative colitis.
authors.affiliation: Inflammatory Bowel Disease Center, The University of Chicago Medicine, Chicago, IL.
authors.forename: Ayal
authors.initials: A
authors.lastname: Hirsch
authors.affiliation: Inflammatory Bowel Disease Center, The University of Chicago Medicine, Chicago, IL ; Section of Gastroenterology, Hepatology and Nutrition, The University of Chicago Medicine, Chicago, IL.
authors.forename: Ruben J
authors.initials: RJ
authors.lastname: Colman
authors.affiliation: Section of Gastroenterology, Hepatology and Nutrition, The University of Chicago Medicine, Chicago, IL.
authors.forename: Gabriel D
authors.initials: GD
authors.lastname: Lang
authors.affiliation: Inflammatory Bowel Disease Center, The University of Chicago Medicine, Chicago, IL ; Section of Gastroenterology, Hepatology and Nutrition, The University of Chicago Medicine, Chicago, IL.
authors.forename: David T
authors.initials: DT
authors.lastname: Rubin